Advertisement

Demographic Profiles and Survival Outcomes of Patients With Urachal Adenocarcinoma: A Rare Tumor of the Urachal Remnant

Published:September 23, 2022DOI:https://doi.org/10.1016/j.clgc.2022.09.008

      Abstract

      Background

      Urachal adenocarcinoma is a rare cancer of a urachal remnant with limited literature and a lack of randomized prospective studies.

      Materials and Methods

      The data of urachal adenocarcinoma cases diagnosed at our institute from January 2013 to March 2021 were retrieved from the electronic medical records. Demographic data were presented using descriptive statistics and simple percentages; survival was calculated using the Kaplan–Meier method.

      Results

      The median age of twenty patients included in the study was 46.5 years with an almost equal male-to-female distribution. Eighteen (90%) patients were diagnosed with Mayo stage 1 to 3 disease at presentation; all of these patients underwent surgical resection of the tumor, while only 8 patients received adjuvant chemotherapy. After a median follow-up of 26.5 months, treatment failure occurred in 7 (38.8%) patients at a median of 12 months. The median disease-free survival (DFS) was 14 (95% CI, 9.1-18.8) months for the 10 patients who did not receive adjuvant chemotherapy, while it was not reached for the 8 patients who received adjuvant chemotherapy. The median progression-free survival (PFS) for the 8 patients treated with palliative chemotherapy was 3 (95% CI, 0-9.5) months and the median overall survival (OS) after the diagnosis of metastasis was 13 (95% CI: 10.1-15.9) months. The median OS of the entire cohort was 42 (95% CI: 20.8-63.2) months.

      Conclusion

      Urachal adenocarcinoma requires multimodality management with the incorporation of adjuvant chemotherapy to achieve favorable clinical outcomes. Further collaborative studies are required to improve survival in this rare cancer.

      Keywords

      Abbreviations:

      BSC (Best supportive care), CI (Confidence Interval), DFS (Disease-free survival), EGFR (Epidermal Growth Factor Receptor), NR (Not Reached), OS (Overall survival), OSm (Overall survival after diagnosis of stage 4), PFS (Progression‑free survival)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Upadhyay V
        • Kukkady A.
        Urachal remnants: an enigma.
        Eur J Pediatr Surg. 2003; 13: 372-376
        • Schubert G.E.
        • Pavkovic M.B.
        • Bethke-Bedurftig B.A.
        Tubular urachal remnants in adult bladders.
        J Urol. 1982; 127: 40-42
        • Begg RC.
        The urachus: its anatomy, histology, and development.
        J Anat. 1930; 64: 170-183
        • Gopalan A
        • Sharp DS
        • Fine SW.
        Urachal carcinoma: a clinicopathologic analysis of 24 cases without come correlation.
        Am J Surg Pathol. 2009; 33: 659-668
        • Mylonas KS
        • O'Malley P
        • Ziogas IA
        • et al.
        Malignant urachal neoplasms: a population-based study and systematic review of the literature.
        Urol Oncol. 2017; 35 (33e11-9)https://doi.org/10.1016/j.urolonc.2016.07.021
        • Henly DR
        • Farrow GM
        • Zincke H.
        Urachal cancer: role of conservative surgery.
        Urology. 1993; 42: 635-639
        • Siefker-Radtke AO
        • Gee J
        • Shen Y
        • et al.
        Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience.
        J Urol. 2003; 169: 1295-1298
        • Pinthus JH
        • Haddad R
        • Trachtenberg J
        • et al.
        Population based survival data on urachal tumors.
        J Urol. 2006; 175: 2042-2047https://doi.org/10.1016/S0022-5347(06)00263-1
        • Paner GP
        • Lopez-Beltran A
        • Sirohi D
        • et al.
        Updates in the pathologic diagnosis and classification of epithelial neoplasms of urachal origin.
        Adv Anat Pathol. 2016; 23: 71-83https://doi.org/10.1097/PAP.0000000000000110
        • Ashley RA
        • Inman BA
        • Sebo TJ
        • et al.
        Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy.
        Cancer. 2006; 107: 712-720
        • Bi Xing
        • Wu Zhiming
        • Han Hui
        • et al.
        Clinical comparison of patients with benign urachal masses versus urachal carcinomas.
        Chin J Cancer. 2017; 36: 2
        • Wiam B.
        • Hamilou Z.
        • Soulieres D.
        • et al.
        Comprehensive and epidemiological characterization of urachal adenocarcinoma: A pan-Canadian collaboration.
        J Clin Oncol. 2019; 37 (516-516)
        • Lee S
        • Lee J
        • Sim SH
        • et al.
        Comprehensive somatic genome alterations of urachal carcinoma.
        J Med Genet. 2017; 54 (Epub 2017 Mar 27): 572-578https://doi.org/10.1136/jmedgenet-2016-104390
        • Kumar N
        • Khosla D
        • Kumar R
        • et al.
        Urachal carcinoma: clinicopathological features, treatment, and outcome.
        J Cancer Res Ther. 2014; 10 (Jul-Sep): 571-574https://doi.org/10.4103/0973-1482.137955
        • Szarvas T
        • Módos O
        • Niedworok C
        • et al.
        Clinical. Prognostic, and therapeutic aspects of urachal carcinoma - a comprehensive review with meta-analysis of 1,010 cases.
        Urol Oncol. 2016; 34: 388-398https://doi.org/10.1016/j.urolonc.2016.04.012
        • Chen D
        • Li Y
        • Yu Z
        • et al.
        Investigating urachal carcinoma for more than 15 years.
        Oncol Lett. 2014; 8 (2014): 2279-2283https://doi.org/10.3892/ol.2014.2502
        • Dhillon J
        • Liang Y
        • Kamat AM
        • et al.
        Urachal carcinoma: a pathologic and clinical study of 46 cases.
        Hum Pathol. 2015; 46: 1808-1814https://doi.org/10.1016/j.humpath.2015.07.021
        • Niedworok C
        • Panitz M
        • Szarvas T
        • et al.
        Urachal carcinoma of the bladder: impact of clinical and Immunohistochemical parameters on prognosis.
        J Urol. 2016; 195: 1690-1696https://doi.org/10.1016/j.juro.2015.11.067
        • Riva G
        • Mian C
        • Luchini C
        • et al.
        Urachal carcinoma: from gross specimen to morphologic, immunohistochemical, and molecular analysis.
        Virchows Arch. 2019; 474: 13-20https://doi.org/10.1007/s00428-018-2467-1
        • Collins DC
        • Velazquez-Kennedy K
        • Deady S
        • et al.
        National incidence, management and survival of urachal carcinoma.
        Rare Tumors. 2016; 8: 6257https://doi.org/10.4081/rt.2016.6257
        • Siefker-Radtke A.
        Urachal adenocarcinoma: a clinician's guide for treatment.
        Semin Oncol. 2012; 39: 619-624https://doi.org/10.1053/j.seminoncol.2012.08.011
        • Bruins HM
        • Visser O
        • Ploeg M
        • et al.
        The clinical epidemiology of urachal carcinoma: results of a large, population-based study.
        J Urol. 2012; 188: 1102-1107
        • Ribic CM
        • Sargent DJ
        • Moore MJ
        • et al.
        Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.
        N Engl J Med. 2003; 349: 247-257
        • Reis H
        • van der Vos KE
        • Niedworok C
        Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas.
        Int J Cancer. 2018; 143 (Epub 2018 May 10): 1764-1773https://doi.org/10.1002/ijc.31547
        • Hamilou Z
        • North S
        • Canil C
        • et al.
        Management of urachal cancer: a consensus statement by the Canadian Urological Association and Genitourinary Medical Oncologists of Canada.
        Can Urol Assoc J. 2020; 14 (Epub 2019 Jul 23): E57-E64https://doi.org/10.5489/cuaj.5946
        • Molina JR
        • Quevedo JF
        • Furth AF
        • et al.
        Predictors of survival from urachal cancer: a Mayo Clinic study of 49 cases.
        Cancer. 2007; 110: 2434-2440https://doi.org/10.1002/cncr.23070
        • Wright JL
        • Porter MP
        • Li CI
        • et al.
        Differences in survival among patients with urachal and non-urachal adenocarcinomas of the bladder.
        Cancer. 2006; 107: 721-728https://doi.org/10.1002/cncr.22059
        • Herr HW
        • Bochner BH
        • Sharp D
        • Dalbagni G
        • Reuter VE.
        Urachal carcinoma: contemporary surgical outcomes.
        J Urol. 2007; 178: 74-78
        • Pavelescu C
        • Pavelescu A
        • Surcel C
        • et al.
        Surgical management of urachal tumors: can the umbilicus be sparred in localized disease?.
        Rare Tumors. 2019; 11 (2036361319847283)https://doi.org/10.1177/2036361319847283
        • Collazo-Lorduy A
        • Castillo-Martin M
        • Wang L
        • et al.
        Urachal carcinoma shares genomic alterations with colorectal carcinoma and may respond to epidermal growth factor inhibition.
        Eur Urol. 2016; 70: 771-775
        • Marcus L
        • Lemery SJ
        • Keegan P
        FDA Approval summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors.
        Clin Cancer Res. 2019; 25: 3753-3758